Arnhold LLC Increases Holdings in Pfizer Inc. (NYSE:PFE)

Arnhold LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 1.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 570,019 shares of the biopharmaceutical company’s stock after purchasing an additional 10,161 shares during the quarter. Pfizer accounts for about 1.8% of Arnhold LLC’s holdings, making the stock its 17th largest holding. Arnhold LLC’s holdings in Pfizer were worth $16,411,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Briaud Financial Planning Inc bought a new position in Pfizer during the 3rd quarter worth approximately $30,000. Mizuho Securities Co. Ltd. bought a new position in Pfizer during the 3rd quarter worth approximately $34,000. VisionPoint Advisory Group LLC grew its position in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the last quarter. GoalVest Advisory LLC grew its position in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new position in Pfizer during the 4th quarter worth approximately $36,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PFE has been the topic of several recent research reports. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Finally, TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $36.33.

Pfizer Stock Down 0.1 %

Shares of NYSE PFE traded down $0.03 during mid-day trading on Tuesday, hitting $25.61. 37,889,007 shares of the stock traded hands, compared to its average volume of 41,962,758. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The company has a market cap of $145.02 billion, a price-to-earnings ratio of 71.14, a PEG ratio of 1.14 and a beta of 0.61. The stock has a fifty day moving average price of $26.88 and a 200-day moving average price of $28.26.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.14 earnings per share. Research analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.56%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.